William Morrone, DO
Addiction Medicine · Essexville, MINPI 1174513766
Payments from drug & device makers
What this record shows
The money is spread across several categories — gifts (49.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by MDD US Operations, LLC at 49.4% of the total. Reporting peaked in 2020 at $8,412 and has fallen 98.2% since, to $148 in 2025. Among addiction medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 41 payments — averaging $414.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$8K
- Janssen Research & Development, LLC$7K
- Orexo US, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$171
- Braeburn Inc.$153
- Indivior Inc.$111
- plus $142 from 2 others
What the payments were for
- Consulting fees$7,07542%
- Travel & lodging$5273%
- Food & beverage$9766%
- Education$150%
- Gifts$8,38849%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MDD US Operations, LLC | 2 | $8,388 |
| Janssen Research & Development, LLC | 6 | $6,811 |
| Orexo US, Inc. | 13 | $1,204 |
| Otsuka America Pharmaceutical, Inc. | 9 | $171 |
| Braeburn Inc. | 3 | $153 |
| Indivior Inc. | 2 | $111 |
| Alkermes, Inc. | 5 | $92 |
| AbbVie | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,980 in reported general payments places this provider in the 95th percentile of 62 addiction medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 15 | $40,630 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 490 | $37,645 |
| BrixadiBuprenorphine | 23 | $36,197 |
| VivitrolNaltrexone Microspheres | 20 | $31,758 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 77 | $22,581 |
| VraylarCariprazine Hcl | 12 | $16,728 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 19 | $3,205 |
| Naltrexone Hcl | 19 | $665 |
| Buprenorphine Hcl | 13 | $497 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $402 |
| Olanzapine | 16 | $361 |
| Pregabalin | 26 | $326 |
| Carbamazepine ErCarbamazepine | 17 | $311 |
| Hydroxyzine Pamoate | 17 | $301 |
| Aripiprazole | 27 | $238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $171 | $40,63015 claims |
| Braeburn Inc.Brixadi | $153 | $36,19723 claims |
| Alkermes, Inc.Vivitrol | $92 | $31,75820 claims |
| Orexo US, Inc.Zubsolv | $1,204 | $22,58177 claims |
| AbbVieVraylar | $50 | $16,72812 claims |
| Indivior Inc.Suboxone | $111 | $3,20519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 62 addiction medicine providers in Michigan.
Other addiction medicine in Essexville
- Alta DerooKalamazoo$53K
- Michael FoxLivonia$39K
- Timothy GammonsSterling Heights$9K
- John CampbellKentwood$8K
- Arun GuptaMonroe$5K
- Morgan FoxLivonia$5K
- Jaswant BaggaAuburn Hills$4K
- Robert McMorrowHoughton Lake$3K
- Yasmin KeshavjeeWarren$3K
- Eric CoffmanBloomfield$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.